WATERTOWN, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in the upcoming conferences.
Read more at globenewswire.comThis article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/AI%20(artificial%20intelligence)/Ai%20chip%20by%20Quality%20Stock%20Arts%20via%20Shutterstock.jpg)
/A%20close-up%20of%20the%20Broadcom%20logo%20on%20a%20smartphone%20by%20Timon%20via%20Adobe%20Stock.jpeg)